Images List Premium Download Classic

Pharmaceutically Acceptable Salt

Pharmaceutically Acceptable Salt-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Probes for imaging huntingtin protein
Hdi Management, Inc.
October 12, 2017 - N°20170292150

Provided are imaging agents comprising a compound of formula (i), or a pharmaceutically acceptable salt thereof, and methods of their use.
Arginine methyltransferase inhibitors and uses thereof
Epizyme, Inc.
October 12, 2017 - N°20170291905

Described herein are compounds of formula (s-i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
Pyrazolo[3,4-c]pyridine derivatives
Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.
October 12, 2017 - N°20170291896

Disclosed are a compound of formula (i), a tautomer, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the above-mentioned compounds. The above-mentioned compounds have the activity of inhibiting xa factor positive effect, and can be used for the preparation of a medicament for preventing and/or treating diseases inhibiting xa factor positive effect in ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Process for the manufacture of idalopirdine via hydrogenation of an imine
H. Lundbeck A/s
October 12, 2017 - N°20170291874

The present invention relates to the preparation of n-(2-(6-fluoro-1h-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (compound i), inn-name idalopirdine, and pharmaceutically acceptable salts thereof:
Method of adjuvant treatment with chlorophyllin containing therapeutic preparation including for radioprotection of normal tissues ...
The Secretary, Department Of Atomic Energy
October 12, 2017 - N°20170290843

A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against γ-radiation toxicity and/or ir-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells ...
Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/...
Asana Biosciences, Llc
October 12, 2017 - N°20170290838

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating ras/raf/mek/erk and pi3k/akt/pten/mtor pathways by administering a therapeutically effective amount of one or more of the compounds of formula (i), wherein x, y, t and ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of hepatitis c virus
Saint Louis College Of Pharmacy
October 12, 2017 - N°20170290827

As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
Teva Pharmaceutical Industries, Ltd.
October 12, 2017 - N°20170290822

This application provides for a method of treating a human patient afflicted with anti-tnfα refractory crohn's disease, of treating a human patient afflicted with non-fibrostenotic crohn's disease, and of treating a human patient whose crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof ...
Small molecule therapies for pulmonary hypertension
Creighton University
October 12, 2017 - N°20170290819

The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.
Novel compounds alpha v beta 6 integrin antagonists
Creighton University
October 12, 2017 - N°20170290818

Wherein r1 is hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.
Benzomorphan analogs and the use thereof
Purdue Pharma L.p.
October 12, 2017 - N°20170290816

In one aspect, the invention provides compounds of formula (i) or (ii): (i) or (ii) and pharmaceutically acceptable salts and solvates thereof, wherein r1, r2a, r2b, r3, r4, z and g are defined as set forth in the disclosure. The invention also provides compounds of formulae a and b and pharmaceutically acceptable salts and solvates thereof. Other aspects ...
Pharmaceutical film composition
Nu Therapeutics Pvt Ltd
October 12, 2017 - N°20170290807

The present invention relates to film compositions of ondansetron or its pharmaceutically acceptable salt thereof, which dosage forms are useful for the treatment of various medical conditions.
Novel small fibre neuropathy treatment
Convergence Pharmaceuticals Limited
October 12, 2017 - N°20170290802

The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Necrosis inhibitors
National Institute Of Biological Sciences, Beijing
October 12, 2017 - N°20170290790

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (rip1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant ...
Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
Sichuan Haisco Pharmaceutical Co., Ltd.
October 12, 2017 - N°20170290781

The present disclosure provides a pharmaceutical preparation of a compound of formula (i) or a stereoisomer, pharmaceutically acceptable salt, or prodrug thereof. The present disclosure further provides a method for general anesthesia or sedation for mammals. Also provided are kits and manufactured products of the medicament and the pharmaceutical composition and a method for using the medicament and the pharmaceutical ...
Soft chewable pharmaceutical products
Intervet, Inc.
October 12, 2017 - N°20170290766

A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.
Soluble c5ar antagonists
Intervet, Inc.
October 05, 2017 - N°20170283446

Including stereoisomers and pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Carm1 inhibitors and uses thereof
Epizyme, Inc.
October 05, 2017 - N°20170283440

Provided herein are compounds of formula (i): (i) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein x, r1, r2a, r2b, r2c, r2d, are as defined herein, and ring het is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of ...
Probes for imaging huntingtin protein
Cchdi Foundation Inc.
October 05, 2017 - N°20170283439

Provided are imaging agents comprising a compound of formula i, or a pharmaceutically acceptable salt thereof, and methods of their use.
Probes for imaging huntingtin protein
Chdi Foundation, Inc.
October 05, 2017 - N°20170283436

Provided are imaging agents comprising a compound of formula (i), or a pharmaceutically acceptable salt thereof, and methods of their use.
Macrocyclic compounds as trk kinase inhibitors
Array Biopharma, Inc.
October 05, 2017 - N°20170283435

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Loading